The Dapper DO retweeted
$NWBO | ACCOUNTABILITY REQUIRES A VOICE
I sent Professor Anthony Chalmers, who is leading the UK’s brain cancer review, a detailed, evidence-based letter urging a comprehensive assessment of DCVax-L, including the latest clinical findings and developments.
I’m sharing that letter publicly for a reason.
Decision-makers need to know we are paying attention. We follow the science, understand the evidence, ask informed questions, and are willing to speak up.
Silence gives those in authority too much latitude to make decisions without meaningful scrutiny. It also leaves room for outside influences and unchallenged assumptions to shape outcomes.
Speaking up isn’t interference. It’s accountability.
We are not asking anyone to abandon scientific standards. We are insisting that those standards be applied fairly, consistently, and transparently.
Scrutiny cannot stop at the treatment. It must extend to the decisions that determine whether patients ever gain access to it.
For Braelyn. For every patient and family waiting for better options.
Our voices deserve to be heard. The evidence deserves to be examined. And every decision deserves accountability.
$NWBO #DCVax #DCVaxForBraelyn #GBM #Glioblastoma #BrainCancer #BTSM #Immunotherapy #PatientAccess
The Dapper DO retweeted
$NWBO
A video letter to President @realDonaldTrump
@HollensbeBrae is the young woman whose Glioblastoma story you recently shared with @DrOzCMS.
Braelyn and her parents live ten minutes from Wednesday’s campaign stop in Clemson and would like to meet you.
“Today she’s 19 years old, attending college, living her life - and her latest MRI shows no evidence of disease.”
Braelyn receives DCVax-L, a promising personalized cancer vaccine developed by American scientists (@NorthwestBio).
But she can’t get it in the U.S. Her family has to travel back and forth to England for compassionate use.
“For three years I fought to save my daughter‘s life and along the way I’ve discovered just how difficult it is for American patients to access promising investigational treatments - even when those treatments were developed right here in their own country.
We need to ask some very serious questions about the barriers facing smaller biotechnology companies, the influence of the pharmaceutical industry, and why patients are left waiting while promising treatments navigate years of regulatory hurdles…
…You signed right-to-try into law and I tremendously appreciate what that legislation was intended to accomplish, but I’ve learned firsthand that having the right to request a treatment doesn’t necessarily mean a patient can actually obtain it…
An American family shouldn’t have to cross an ocean to receive a promising cancer treatment developed by American scientists…”
— @HollensbeAmanda
The Dapper DO retweeted
$NWBO 𝗗𝗖𝗩𝗮𝘅-𝗟: 𝗡𝗛𝗦𝗕𝗧 𝗖𝗢𝗟𝗟𝗘𝗖𝗧𝗜𝗢𝗡𝗦 𝗔𝗥𝗘 𝗟𝗜𝗩𝗘. 𝗖𝗨𝗥𝗥𝗘𝗡𝗧 𝗔𝗖𝗖𝗘𝗦𝗦 𝗔𝗡𝗗 𝗖𝗢𝗠𝗠𝗘𝗥𝗖𝗜𝗔𝗟 𝗣𝗥𝗘𝗣𝗔𝗥𝗔𝗧𝗜𝗢𝗡 𝗔𝗥𝗘 𝗠𝗢𝗩𝗜𝗡𝗚 𝗧𝗢𝗚𝗘𝗧𝗛𝗘𝗥.
I contacted NHSBT directly to clarify what is operational, how patients enter the pathway, and what the collaboration is intended to support.
Their response confirms:
“Yes, the service is currently live and collections have already begun.”
𝗟𝗲𝗲𝗱𝘀 𝗮𝗻𝗱 𝗢𝘅𝗳𝗼𝗿𝗱 𝗮𝗿𝗲 𝗼𝗽𝗲𝗻. DCVax-L patient collections through NHSBT are happening now.
𝗕𝗢𝗧𝗛 𝗕𝗘𝗙𝗢𝗥𝗘 𝗔𝗡𝗗 𝗔𝗙𝗧𝗘𝗥 𝗔𝗣𝗣𝗥𝗢𝗩𝗔𝗟
I specifically asked whether the collaboration supports existing compassionate-use/unlicensed treatment arrangements, preparation for commercial rollout following MHRA marketing authorisation, or both.
The answer:
“Both.”
That establishes the purpose of this infrastructure: serving patients under current access arrangements while preparing to support commercial use following an approval.
𝗘𝗫𝗣𝗔𝗡𝗦𝗜𝗢𝗡 𝗜𝗦 𝗣𝗥𝗢𝗕𝗔𝗕𝗟𝗘 𝗕𝗘𝗙𝗢𝗥𝗘 𝗠𝗔𝗥𝗞𝗘𝗧𝗜𝗡𝗚 𝗔𝗨𝗧𝗛𝗢𝗥𝗜𝗦𝗔𝗧𝗜𝗢𝗡
NHSBT’s exact wording:
“Expansion is probable in advance of marketing authorisation.”
Additional sites and potential start dates are already being negotiated. NHSBT said these details can be shared once confirmed.
This means network development can progress before a regulatory decision. Leeds and Oxford are the two locations confirmed operational today; further locations are being actively discussed.
𝗧𝗛𝗘 𝗦𝗖𝗔𝗟𝗜𝗡𝗚 𝗦𝗜𝗚𝗡𝗜𝗙𝗜𝗖𝗔𝗡𝗖𝗘
NWBO and Advent already have functioning collection services within established NHSBT clinical infrastructure. Additional locations would extend that pathway geographically, connecting more patients with an essential step in personalised vaccine production.
Current patient access, operational experience and preparation for broader commercial use are developing together.
The email establishes a live service and an active expansion process. DCVax-specific annual collection capacity and manufacturing throughput were not provided.
𝗔 𝗖𝗢𝗡𝗖𝗥𝗘𝗧𝗘 𝗧𝗜𝗠𝗘𝗙𝗥𝗔𝗠𝗘 𝗔𝗡𝗗 𝗥𝗘𝗙𝗘𝗥𝗥𝗔𝗟 𝗥𝗢𝗨𝗧𝗘
NHSBT says it can usually accommodate a patient within 𝟮 𝘄𝗲𝗲𝗸𝘀.
The referral pathway is:
𝗥𝗲𝗳𝗲𝗿𝗿𝗶𝗻𝗴 𝗰𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁 → 𝗔𝗱𝘃𝗲𝗻𝘁 𝗕𝗶𝗼𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 → 𝗡𝗛𝗦𝗕𝗧.
The consultant contacts Advent, which then makes the NHSBT referral. Physicians have an identified route into the collection service.
The two-week timeframe applies to NHSBT’s stage. Advent’s separate waiting time was not confirmed, so the complete schedule through assessment, manufacturing and treatment still needs clarification.
𝗛𝗢𝗪 𝗖𝗨𝗥𝗥𝗘𝗡𝗧 𝗔𝗖𝗖𝗘𝗦𝗦 𝗜𝗦 𝗙𝗨𝗡𝗗𝗘𝗗
NHSBT confirmed that patients currently self-fund treatment because it is not commissioned by NHS England.
NHSBT is delivering services within that pathway. Its participation does not establish NHS-funded treatment. Patient charges and NHSBT’s financial terms were not disclosed.
𝗧𝗛𝗘 “𝗔𝗟𝗟 𝗦𝗢𝗟𝗜𝗗 𝗧𝗨𝗠𝗢𝗨𝗥𝗦” 𝗤𝗨𝗘𝗦𝗧𝗜𝗢𝗡
My question about this wording, current patient eligibility and its relationship to the MHRA application was referred to Simon Cliffe for clarification.
Her reply did not establish the scope of current eligibility across tumour types or a future approved indication.
𝗜 𝗛𝗔𝗩𝗘 𝗔𝗟𝗥𝗘𝗔𝗗𝗬 𝗦𝗘𝗡𝗧 𝗔 𝗙𝗢𝗟𝗟𝗢𝗪-𝗨𝗣
I am a physician and independent patient advocate. I do not work for NWBO or Advent. I am receiving substantial enquiries from patients and families, including people in the United States interested in UK access.
I have sent another email asking for:
• The appropriate Advent contact and a coordinator for the complete pathway.
• Whether US physicians can initiate referrals directly or patients first need a UK consultant.
• When NHSBT’s two-week timeframe begins, plus separate assessment and manufacturing waiting times.
• Whether eligibility, tumour-tissue suitability, costs and appointments can be confirmed before international travel, and how many UK visits are required.
• A written referral checklist that can be shared with patients and their physicians.
Jemima also offered a call, which I welcomed in my reply. My aim is to help patients and their doctors understand the complete process and coordinate access to this operating service.
Source: written correspondence with Jemima Churchhouse, Service Development Manager, NHSBT Therapeutic Apheresis Services, 12 October 2026.
#DCVax #GBM #CancerImmunotherapy #UKLifeSciences #DCVaxForBraelyn
Out of respect for the person who took the time to respond, I’m keeping direct screenshots of the email off X. I’m sharing the substantive information provided and am awaiting a response to my follow-up questions. I’ll share further clarification when I receive it.
$NWBO #DCVax #DCVaxForBraelyn #GBM #SolidTumors #CancerVaccines
𝗧𝗛𝗘 𝗡𝗛𝗦 𝗖𝗢𝗡𝗡𝗘𝗖𝗧𝗜𝗢𝗡 𝗧𝗢 𝗗𝗖𝗩𝗮𝘅 𝗜𝗦 𝗔𝗟𝗥𝗘𝗔𝗗𝗬 𝗢𝗣𝗘𝗥𝗔𝗧𝗜𝗡𝗚
A manufacturing bottleneck that affected patients now has a named NHS operating partner.
On April 21, Northwest reported difficulty obtaining timely leukapheresis appointments for its UK compassionate-use programme. Patients could deteriorate while waiting for the white-cell collection needed to manufacture treatment. The company announced a dedicated clinic at the London Welbeck Hospital to address that constraint.
On October 8, NHS Blood and Transplant (NHSBT) confirmed that its teams were collecting cells and providing specialist processing and handling for DCVax-L. The collaboration initially involves Leeds and Oxford, follows months of joint work and includes exploration of expansion to further NHSBT locations. Its Cellular and Molecular Therapies service has also acknowledged the contribution of its Stem Cell Processing Laboratories, naming Advent and Northwest.
For a therapy made from a patient’s own material, access to collection is part of access to treatment.
𝗔𝗡 𝗜𝗗𝗘𝗡𝗧𝗜𝗙𝗜𝗘𝗗 𝗕𝗢𝗧𝗧𝗟𝗘𝗡𝗘𝗖𝗞 𝗡𝗢𝗪 𝗛𝗔𝗦 𝗔𝗡 𝗡𝗛𝗦 𝗣𝗥𝗢𝗗𝗨𝗖𝗧𝗜𝗢𝗡 𝗣𝗔𝗥𝗧𝗡𝗘𝗥
NHSBT brings established expertise and facilities to the beginning of the production pathway. Its apheresis network spans ten English cities, with Leeds and Oxford named in this collaboration. Extending that starting model would give more patients a route into manufacture through existing services.
Personalised manufacture can fit inside care a patient is already receiving. In the phase III programme, the batch was produced during postoperative chemoradiotherapy and stored for later dosing. The April release identified an earlier bottleneck: obtaining the collection appointment needed to start that process. NHSBT adds capacity at precisely that entry point. Its practical value begins with getting the patient’s cells into the planned treatment sequence.
Properly authorised compassionate treatment can proceed before marketing approval through the applicable UK unlicensed-medicine arrangements. Advent holds a Specials licence for cell therapy products at Sawston. Northwest reported patient manufacture there from Q1 2022, following Specials and trial licences obtained in late 2021.
Access is assessed through the treating team, with individual arrangements for supply and funding. Marketing authorisation and routine NHS commissioning are separate decisions. The NHSBT partnership strengthens the production support needed for treatment plans that can be made now.
𝗡𝗢𝗪 𝗣𝗨𝗧 𝗢𝗖𝗧𝗢𝗕𝗘𝗥 𝟲 𝗕𝗔𝗖𝗞 𝗜𝗡𝗧𝗢 𝗧𝗛𝗘 𝗣𝗜𝗖𝗧𝗨𝗥𝗘
Two days before the production announcement, the conference programme placed the NHS Cancer Vaccine Launch Pad (CVLP) at 12:35 and Bosch’s personalised, multi-target immunotherapy keynote at 12:55.
The sequence brought the trial-access framework and the cellular platform before the same oncology audience, while a separate NHS operating relationship was already being developed.
CVLP’s protocol covers personalised cancer-vaccine trials requiring biological samples for manufacture and accommodates multiple cancer types, trials and partners. A DCVax-L trial proposal fits that category. CVLP can identify and refer patients into accepted studies; NHSBT can support collection and handling; specialist manufacture can supply the product. Formal DCVax participation in CVLP remains unannounced.
The October 8 agreement gives the conference positioning operational substance: a named NHS organisation is already doing essential work in the production pathway.
𝗙𝗢𝗟𝗟𝗢𝗪 𝗧𝗛𝗘 𝗧𝗪𝗢 𝗜𝗡𝗣𝗨𝗧𝗦
DCVax-L begins with tumour material obtained during surgery and monocytes collected from the patient’s blood.
The tumour supplies the antigen repertoire. The monocytes supply the cells developed into dendritic cells outside the body. Manufacturing brings the two together, preparing an antigen-presenting cell carrying information from that patient’s cancer.
The incoming material has a demanding journey. Northwest’s annual report describes fresh tissue and cells that must reach manufacturing within a defined window, in usable condition. Chain of identity keeps the material linked to its patient; chain of custody records the handoffs.
NHSBT’s announced contribution is collection and cellular handling. Advent supplies specialist manufacturing at Sawston. Every part has to work for the patient-specific batch to reach treatment.
𝗢𝗡𝗘 𝗠𝗔𝗡𝗨𝗙𝗔𝗖𝗧𝗨𝗥𝗜𝗡𝗚 𝗥𝗨𝗡 𝗖𝗔𝗡 𝗦𝗨𝗣𝗣𝗢𝗥𝗧 𝗠𝗔𝗡𝗬 𝗩𝗜𝗦𝗜𝗧𝗦
The published phase III process produced individual frozen doses from one patient-specific batch. A full batch supplied ten doses on the trial’s schedule.
That is a major logistical advantage. Repeat treatment need not require a new operation, a new collection and a new manufacturing run before every injection. The initial production effort creates a supply for later visits.
The company and Bosch describe about eight days for DCVax-L manufacture, followed by quality and release testing. In the phase III programme, production took place during postoperative chemoradiotherapy. Personalised manufacture was integrated into the existing treatment sequence.
Cryogenic storage then separates the production date from the treatment date, subject to validated stability and handling. The next dose can already be made when the next visit is due.
𝗧𝗛𝗘 𝗟𝗔𝗦𝗧 𝗝𝗢𝗨𝗥𝗡𝗘𝗬 𝗜𝗦 𝗕𝗜𝗢𝗟𝗢𝗚𝗜𝗖𝗔𝗟
The released dose is delivered frozen and prepared for an intradermal injection into the upper-arm skin.
The purpose is an immune encounter. Dendritic cells can migrate towards draining lymph nodes, present antigen and help organise tumour-directed T-cell activity. Antigen recognition, costimulation and appropriate cytokine instruction work together. Activated helper T cells can reinforce receptive dendritic cells through CD40L–CD40 licensing.
This explains why a living-cell product needs more than correct labelling and transport. The cells must retain the function needed to perform their part of the response. Bosch’s slides connect the argument to human observations: antigen display, expanded T-cell clones and T cells present in glioblastoma (GBM) tissue after upper-arm vaccination.
The logistics protect the biological work the treatment is intended to do.
𝗧𝗛𝗘 𝗖𝗟𝗜𝗡𝗜𝗖𝗔𝗟 𝗙𝗢𝗨𝗡𝗗𝗔𝗧𝗜𝗢𝗡 𝗙𝗢𝗥 𝗪𝗜𝗗𝗘𝗥 𝗗𝗘𝗩𝗘𝗟𝗢𝗣𝗠𝗘𝗡𝗧
The published phase III externally controlled analysis provides the principal clinical foundation for DCVax-L development. In newly diagnosed GBM, median overall survival from randomisation was 19.3 months with DCVax-L versus 16.5 months in the external controls; estimated five-year survival was 13.0% versus 5.7%. In recurrent GBM, the median comparison was 13.2 versus 7.8 months from recurrence.
An organised treatment service can also make future evidence stronger. Manufacturing records identify which product a patient received. Consented clinical follow-up records what happened afterwards. Connecting them prospectively would make compassionate-use experience more useful for subsequent development.
𝗔𝗗𝗩𝗘𝗡𝗧 𝗢𝗪𝗡𝗘𝗥𝗦𝗛𝗜𝗣 𝗖𝗢𝗡𝗡𝗘𝗖𝗧𝗦 𝗧𝗛𝗘 𝗧𝗘𝗖𝗛𝗡𝗢𝗟𝗢𝗚𝗬 𝗧𝗢 𝗜𝗧𝗦 𝗘𝗫𝗘𝗖𝗨𝗧𝗜𝗢𝗡
Northwest acquired all of Advent on October 24, 2025. Advent brought the organisation responsible for manufacturing, quality and release testing, storage, distribution and product-development work into the group.
Northwest already owned Flaskworks. Owning the automation technology and the manufacturing organisation puts the engineering and its implementation under one corporate owner. Staffing, facility investment, process changes and clinical supply can be coordinated inside that group.
The closing release explicitly connected this integration to additional applications, next-generation technologies and what Linda Powers called a “dominant franchise.” The repeatable asset is an organisation that can turn process knowledge into controlled production. That is why Advent matters beyond one site or one indication.
𝗧𝗛𝗘 𝗦𝗧𝗔𝗙𝗙𝗜𝗡𝗚 𝗦𝗛𝗢𝗪𝗦 𝗧𝗛𝗘 𝗪𝗢𝗥𝗞 𝗕𝗘𝗛𝗜𝗡𝗗 𝗧𝗛𝗘 𝗣𝗟𝗔𝗧𝗙𝗢𝗥𝗠
As of October 9, Advent was recruiting a Biobank Technician for its biological-sample storage services. The advert seeks biobank experience under good manufacturing practice (GMP), with cryogenic storage, laboratory information management systems (LabWare/LIMS) and regulatory audits among the desired skills. It also includes covering for the Biobank lead. Applications go directly to Advent by email.
Robert Ridenour has separately announced that he is starting as Northwest’s Director of Information Technology. That is a role at the parent company, distinct from Advent’s vacancy.
The connection is information continuity. Scaling an autologous therapy multiplies patient-specific identities as well as batches. The patient, the biological material and the records must remain linked through collection, processing, manufacture, storage and delivery.
The biobank role concerns Advent’s general storage business. Its relevance to this analysis is the operating discipline it makes visible: living material must arrive in usable condition with a trustworthy record of whose material it is and how it has been handled.
𝗘𝗗𝗘𝗡 𝗔𝗗𝗗𝗥𝗘𝗦𝗦𝗘𝗦 𝗧𝗛𝗘 𝗡𝗘𝗫𝗧 𝗖𝗔𝗣𝗔𝗖𝗜𝗧𝗬 𝗖𝗢𝗡𝗦𝗧𝗥𝗔𝗜𝗡𝗧
The Flaskworks team documented the EDEN name in a 2018 research paper. Northwest’s later DCVax-L automation programme aims to reproduce the relevant characteristics of the established product through a closed process. Its February 2024 update reported substantially comparable composition, function, purity and dose yield from the optimised prototype.
The proposed gain is more separate patient batches supported by the same laboratory space and specialist workforce, with fewer manual steps. Each patient’s material remains separate.
Deployment requires equipment qualification, process validation, comparability and acceptance for the intended manufacturing use. The 2025 annual report still described development and stated that the systems had not operated at commercial scale. Those steps establish the distinction between demonstrated prototype performance and accepted production capacity.
Existing manufacture already supports current supply. In the supplied December 2025 meeting transcript, management said it would “anticipate launching, with just the two existing Grade B suites,” with Grade C intended to add capacity. Eden’s significance is the capacity and economics of reproducing the product as the service grows.
𝗧𝗛𝗘 𝗙𝗜𝗟𝗜𝗡𝗚𝗦 𝗦𝗛𝗢𝗪 𝗔 𝗪𝗜𝗗𝗘𝗥 𝗖𝗔𝗣𝗔𝗖𝗜𝗧𝗬 𝗦𝗧𝗥𝗔𝗧𝗘𝗚𝗬
The June 2026 quarterly report describes several ways to expand the same pathway: obtain collection capacity through existing facilities without capital expenditure, explore additional tumour-lysate processing locations, discuss a second UK production operation and pursue grant funding for Sawston.
Each addresses a different constraint. More collection appointments supply starting material. Additional processing capability can release central capacity. Automation targets the labour and space required for manufacture.
The UK already has a relevant operating precedent. Autolus established company-controlled production inside Cell and Gene Therapy Catapult’s Stevenage centre, with Innovate UK project support, its own process and its own recruited team. Catapult also operates Braintree facilities. Northwest has not identified either as its second-site partner; its disclosed grant pursuit concerns Sawston.
NHSBT has four licensed advanced-cell manufacturing laboratories and expertise in development, technology transfer, manufacture, release, storage and logistics. Its reference to exploring broader laboratory collaboration therefore reaches well beyond the collection appointment.
𝗧𝗛𝗘 𝗖𝗔𝗣𝗔𝗕𝗜𝗟𝗜𝗧𝗬 𝗖𝗔𝗡 𝗧𝗥𝗔𝗩𝗘𝗟
The US disclosures show how that programme can expand. In late 2025, Northwest described site selection and recruitment for its in-licensed technologies. By June 2026 it reported completed DCVax-L technology transfer, engineering runs and validation at a US company. It was also considering a parallel transfer there for the Kalinski products while separate lease negotiations continued.
A company can carry process knowledge, specifications, training and quality oversight into qualified facilities without constructing and owning every building. Each product and site needs its own validation and permissions.
The non-binding SPIMACO memorandum adds a named regional route: discussions cover DCVax-L approval, supply and commercialisation in Saudi Arabia, with separately negotiated localisation and technology transfer. It starts with GBM and allows mutually agreed expansion.
This connects Advent, NHSBT and the Catapult precedent: retain control of the work that makes a personalised therapy reproducible, then use established infrastructure to extend the programme.
𝗧𝗛𝗘 𝗣𝗟𝗔𝗧𝗙𝗢𝗥𝗠 𝗢𝗣𝗣𝗢𝗥𝗧𝗨𝗡𝗜𝗧𝗬 𝗘𝗫𝗧𝗘𝗡𝗗𝗦 𝗕𝗘𝗬𝗢𝗡𝗗 𝗚𝗕𝗠
Bosch’s overview describes 16 tumour types treated in DCVax clinical trials, plus additional compassionate-use cases. The presentation includes ovarian-cancer observations and Direct’s phase I programme in 40 patients across 13 tumour types.
DCVax-L receives tumour material obtained during surgery. Direct addresses inoperable tumours by placing prepared cells into tumour tissue to acquire antigen there. They connect the patient’s cancer to the presenting cell at different points.
One of Bosch’s Direct slides follows five lesions in a clear-cell sarcoma patient after injection into only one lesion. Several uninjected lesions also fell below their screening measurements. The significance is activity beyond the injection site: an individual clinical observation supporting further investigation of systemic immune effects from local treatment.
Advent also solved a documented manufacturing problem for Direct after an earlier contractor failed to meet specification. Northwest reported completion of its Sawston transfer programme in 2025. Bosch describes Direct manufacture as closed and automated; this is distinct from proving deployment of the Eden implementation for L. The next clinical programme still requires its own authorisation, sites and funding.
The broader development opportunity is to combine complete compassionate-use records, prospective cancer cohorts and reliable supply to establish benefit in defined populations. Those data can support applications for additional indications.
There is a public-funding precedent: the National Institute for Health and Care Research (NIHR) funded ImmunoTACE, a different dendritic-cell vaccine programme in liver cancer. NHS England funds CVLP. NIHR’s Efficacy and Mechanism Evaluation (EME) researcher-led call is open as of October 9, with outline applications due November 25, 2026. An eligible team can develop a defined proposal this autumn, with a sponsor, supply arrangements and a budget.
𝗧𝗛𝗘 𝗟𝗜𝗖𝗘𝗡𝗦𝗘𝗗 𝗧𝗘𝗖𝗛𝗡𝗢𝗟𝗢𝗚𝗜𝗘𝗦 𝗚𝗜𝗩𝗘 𝗧𝗛𝗔𝗧 𝗔𝗥𝗖𝗛𝗜𝗧𝗘𝗖𝗧𝗨𝗥𝗘 𝗠𝗢𝗥𝗘 𝗧𝗢 𝗗𝗘𝗩𝗘𝗟𝗢𝗣
The Roswell Park and Pittsburgh portfolios extend the programme through enhanced dendritic-cell preparations, conditioning approaches and combination strategies. The Roswell licence includes antigen-loaded dendritic-cell therapies and versions intended to acquire antigen after intratumoral administration.
The biological task is coordinated immune instruction. The presenting cell needs suitable antigen information, the functional signals to direct a cellular response, and a route into the relevant immune encounter. Type-1-polarized preparations aim to preserve that instructional capacity. This is more than a question of how much cytokine a cell produces.
Bosch and Bhandary’s New York Academy of Sciences (NYAS) work on dendritic cells prepared for intratumoral injection shows why controlled preparation matters. Different combinations changed cytokine and migration-related profiles; the summary reported additive, complementary and antagonistic effects. Those laboratory findings guide clinical development of candidate preparations.
The September 2025 filing explicitly connects the licensed portfolios to new Direct trial designs involving conditioning, accompanying agents and additional administration routes. The company is developing a broader treatment programme around the cellular therapy.
𝗧𝗛𝗜𝗦 𝗛𝗔𝗦 𝗔 𝗣𝗥𝗘𝗦𝗘𝗡𝗧 𝗣𝗨𝗥𝗣𝗢𝗦𝗘 𝗔𝗡𝗗 𝗔 𝗪𝗜𝗗𝗘𝗥 𝗗𝗘𝗩𝗘𝗟𝗢𝗣𝗠𝗘𝗡𝗧 𝗣𝗔𝗧𝗛
The strategic asset is a controlled treatment process that can be repeated around different patients’ biological material.
NHSBT strengthens the route into production. Advent places manufacturing execution inside Northwest. Eden targets the next capacity step, and the licensed technologies extend the clinical-development programme. Existing compassionate supply gives that infrastructure a present purpose.
The October 6 conference placed the platform beside a national access framework. The October 8 announcement showed NHS teams already supporting its production. The opportunity is to extend that operating capability, generate the evidence for additional uses and secure the corresponding access and funding decisions.
The treatment is personal. The service has to be dependable at every handoff. That is the importance of the NHS connection.
Sources
NHSBT collaboration: prnewswire.com/news-releases…
April capacity statement: nwbio.com/northwest-biothera…
Bosch presentation: nwbio.com/wp-content/uploads…
CVLP: southampton.ac.uk/ctu/cancer…
MHRA access guidance: gov.uk/guidance/advanced-the…
NIHR funding call: nihr.ac.uk/funding/eme-progr…
Advent acquisition: nwbio.com/northwest-biothera…
June 2026 quarterly filing: sec.gov/Archives/edgar/data/…
Autolus precedent: ct.catapult.org.uk/resources…
Licensed portfolio: nwbio.com/northwest-biothera…
NYAS presentation: nwbio.com/wp-content/uploads…
September 2025 filing: sec.gov/Archives/edgar/data/…
Historical EDEN publication: doi.org/10.18609/cgti.2018.1…
Patient manufacture at Sawston: nwbio.com/northwest-biothera…
Advent employer recruitment: uk.linkedin.com/company/adve…
Saudi memorandum: nwbio.com/northwest-biothera…
Phase III publication: jamanetwork.com/journals/jam…
Direct clinical report: pubmed.ncbi.nlm.nih.gov/3001…
2025 annual report: sec.gov/Archives/edgar/data/…
December 2025 management discussion: supplied transcript; official meeting date verified at nwbio.com/annual-shareholder…
IT appointment: Robert Ridenour’s LinkedIn announcement, reproduced in the accompanying image; profile at linkedin.com/in/robertrideno…
The Dapper DO retweeted
I have recently received a harsh personal attack...and my board members @immortabio have been contacted...by people complaining that I support $NWBO
You know what this means?
WAR
I shall amplify my posts supporting the most advanced and promising dendritic cell technology !
The Dapper DO retweeted
This video stopped me in my tracks.
Kristen paired the words from my letters with images that tell the rest of the story — Braelyn immediately after brain surgery, receiving DCVax, exploring London between treatments, beginning her college classes, and finally back home surrounded by the people she loves.
That is what we are fighting for.
Not simply another scan. Not simply “more time.” We are fighting for her future — college, travel, family, laughter, ordinary days and all the milestones a 19-year-old should be able to dream about.
Thank you, Kristen, for taking our story and showing so beautifully what is actually at stake when families ask regulators for urgency.
$NWBO
Amanda Hollensbe is fighting to save her daughter Braelyn’s life.
She wrote this letter to the UK Prime Minister and the Chief Executive of the MHRA
Braelyn spent much of the summer in London so she could get her first three doses of DCVax - a non-toxic glioblastoma vaccine made by an American company.
A promising treatment U.S. regulators still won’t approve.
The data is there.
10-and 20-year + glioblastoma survivors exist.
The UK gave her a chance.
Regulators everywhere are still moving like they have all the time in the world.
Glioblastoma patients don’t.
Video #11 (other videos are in this thread. Please repost)
@HollensbeAmanda @gr197667 @andrewcaravello @MHRAgovuk @RobertKennedyJr
The Dapper DO retweeted
#dcvax $nwbo #gbm
Big news !!!
"I've been so excited to share some big news with you! From the beginning, Cancer Vaccine Coalition was built for one thing: to be a catalyst.
Our mission was to break down silos and build global collaborations to accelerate cancer vaccines. We vowed to follow the science, and find the very best path to get cutting edge treatments to patients sooner. It was never about building a non-profit, it was about building a MOVEMENT. We never wanted to do it alone.
Today the Cancer Vaccine Coalition is thrilled to announce a strategic integration with the Parker Institute for Cancer Immunotherapy (PICI,) a trail-blazing non-profit known for making big bets on bold research, and bringing together the world’s brightest minds to cure cancer using our immune systems.
Sound familiar? We thought so too.
Founded in 2016, by tech pioneer Sean Parker, PICI shares CVC’s aim to build the most ambitious and collaborative engine in cancer research. PICI doesn’t just fund research, it is literally redesigning the system around it, with an urgency that matches our own.
After meeting with Sean, and PICI’s CEO, Karen Knudsen (former CEO of the American Cancer Society!) I knew this was the perfect match to help us take what we have built from aspirational to operational.
PICI is already doing many of the things on our list: building a coordinated network of leading cancer centers where trials are designed and launched together. Data is shared in real time, and discoveries don’t sit in silos but are actively brought into companies who drive clinical trials to ensure breakthroughs move more quickly toward patients.
With PICI embracing cancer vaccines as a scientific priority, it made sense to not just work together, but to formally join together. As of today, CVC is taking its mission, urgency, passion and patient focus—and embedding it where it can move faster and reach further.
I will be joining PICI’s executive leadership team as the new Chief External Affairs Officer and will continue my work as a catalyst and a champion for better treatments. I couldn’t be more excited!
CVC was never about a name… or a 501C3. It was about building something world changing.
So, while, technically, CVC will no longer be its own legal entity, our mission is very much intact. In fact, finding a like minded organization to launch us to the next level feels like the BEST thing that could happen for cancer vaccines.
Lastly, no matter what we’re called, this ‘coalition’ has always been about you. This is not the last you will hear about incredible research, enrolling clinical trials and key milestones on the road to vaccines.
I am so proud of what we have accomplished together. I am eternally grateful to the CVC team, the scientists doing this incredible research, and ALL OF YOU.
What a ride this has been!! It is by no means over… I have never been more HOPEFUL!
Cheers to you, this new PICI Partnership and our best ‘shot’ at getting vaccines to patients SOONER!
With gratitude"
Kristen and the entire CVC/PICI Team
Gemini AI Analysis of synergy and potential for DCVax platform technology:
The strategic integration between the Cancer Vaccine Coalition (CVC) and the Parker Institute for Cancer Immunotherapy (PICI) is a landmark move for the oncology sector. For companies like Northwest Biotherapeutics (NWBO), this consolidation of resources and "big bet" mentality creates a significant tide that could lift their specific boat.
Here is an analysis of the synergy and what this means for NWBO.
1. The Synergy: "Speed Meets Scale"
The merger combines CVC’s mission-driven focus on accelerating clinical timelines with PICI’s massive infrastructure and network of elite research institutions (including Stanford, UPenn, and MD Anderson).
Financial Powerhouse: PICI is known for funding high-risk, high-reward research that traditional VC might avoid. Their backing provides a "stamp of approval" that can trigger secondary investment.
Standardization of Trials: One of the biggest hurdles for vaccines like NWBO’s DCVax-L is the complexity of personalized manufacturing and trial protocols. A unified CVC-PICI front can help standardize these "next-gen" trial designs, making regulatory approval paths clearer for all players.
2. The Impact on Northwest Biotherapeutics (NWBO)
While NWBO is an independent public company, its interests are deeply aligned with this new coalition.
The "Global Think Tank" Connection
Earlier in 2026, Northwest Biotherapeutics was a key supporter of the Global Think Tank hosted by the CVC (alongside giants like Pfizer). This indicates that NWBO is already "in the room" where these strategic priorities are being set.
Synergy: By being an early partner of the CVC, NWBO is now positioned within the broader PICI ecosystem. This provides NWBO with potential access to PICI’s clinical trial network, which could accelerate any future combination trials or label expansions for DCVax.
Validation of the "Platform" Approach
PICI and CVC focus heavily on therapeutic vaccines and interception (stopping cancer before it returns). This perfectly mirrors NWBO’s strategy with DCVax:
DCVax-L (Glioblastoma): Fits the "therapeutic" mold.
DCVax-Direct (Solid Tumors): Fits the "platform" mold that PICI loves to fund for multi-cancer applications.
Summary Report:
The CVC-PICI integration acts as a force multiplier for the entire cancer vaccine field. For NWBO, the primary benefit is ecosystem validation. As a company that has fought for years to prove the viability of dendritic cell vaccines, having a powerhouse like PICI consolidate the field around this exact technology provides the regulatory and institutional "tailwinds" NWBO needs as it moves toward potential commercialization and broader clinical applications.
Key takeaway: The merger doesn't just provide more money; it provides a more efficient highway for NWBO’s therapies to move from the lab to the pharmacy.
prnewswire.com/news-releases…
The Dapper DO retweeted
Our daughter Braelyn (18) just underwent a 6.5+ hour brain tumor surgery at UCLA yesterday with world-renowned neurosurgeon Dr. Linda Liau.
She was originally given 1–3 months to live.
That was 31 months ago.
Yesterday’s surgery removed ~90% of the tumor and may open the door to personalized immunotherapy.
Here’s what happened yesterday:🧵
The Dapper DO retweeted
$NWBO Great news here. This is proof of how legitimate #DCVax is becoming. All things are moving in our direction. Northwest Bio is the only named company in the article prnewswire.com/news-releases…
The Dapper DO retweeted
How Northwest Biotherapeutics’ acquisition of Advent BioServices may reshape its cell therapy strategy business-news-today.com/how-… #NorthwestBiotherapeutics #AdventBioServices #DCVax #Immunotherapy #CellTherapy #BiotechNews #GBM #NWBO #CancerVaccine #BiotechAcquisition
RT @andrewcaravello: 🚨 The Gate Rewritten: How $NWBO #DCVax Became the Model for FDA’s New Era
TLDR — FDA rewrites the code
On September 2…
This quoted post is unavailable.
The Dapper DO retweeted
📊Abnormal Stock Behavior
$NWBO
Here is a chart showing the expected share price behavior of a company while in regulatory review for a drug approval. See Image 1. It shows significant share price appreciation.
Here is $NWBO's market cap chart since the MAA submission to the MHRA on December 21, 2023. See Image 2. It shows significant market cap depreciation.
Here is the expected return for a biotech company one year before and 3 days after an approval. See Image 3. It shows a ~50% return the year leading up to approval and a ~20% return in the 3 days following approval.
Here is $NWBO's one year chart. See Image 4. It shows a negative return.
➡️Thoughts
There is a reason why $NWBO, despite all the drawbacks of engaging in litigation, had their hand forced in filing the spoofing lawsuit.
The attached charts are not perfect comparisons to $NWBO's situation but it shows $NWBO is acting nothing like it should. These charts are dealing with FDA submissions from years prior, the charts generally contain data from larger companies where an approval will have less impact on share price and I compare $NWBO's market cap chart to a share price chart (to negate any argument that $NWBO's share price has gone down because of dilution). Regardless, from all the studies I see looking at regulatory submissions of a drug and how it impacts share price, $NWBO is an extreme outlier, in a bad way.
Charts from here: digitalcommons.pepperdine.ed…
This goes hand-in-hand with my earlier post where I opine that America's innovative spirit is being destroyed by those looking to [il]legally profit off of the destruction of companies: xitter.cf/hoffmann6383/status/19…
💰The Vulture Capitalist: American Innovation at its’ Worst
In this post I take a look at why the US is seeing a declining biotech IPO trend as compared to other countries.
Ernst & Young (“EY”) recently published a reported titled "Global IPO Trends, Q2 2025". [1] The report points out that South Korea's health and life sciences sector "saw increases in deal count and proceeds compared to the same period last year." India's pipeline remained "particularly strong" in health care. Further, China's "Health and Life Sciences remained highly active." On the other hand the EY report stated that the US "Health and Life Sciences sector remained challenged".
➡️How 'challenged' is the US IPO trend in biotech?
Image 1 looks at US biotech deals by year and stage of development. It shows a significant decline in US biotech IPOs over the last few years. Further, it shows a shift to IPOs for biotech companies in later stages of development. See Image 1. In fact, EY’s data showed China raising more IPO dollars for the health and life sciences area than that raised by the US markets for Q1 '25. See Image 2.
Barclays described the biopharma IPO market in the US as “challenging”. [2]
Two senior life science analyst described the biopharma IPO market as “sluggish”. [3] They described the last several years of life sciences IPOs as “moribund”. [3]
Biopharma Dive stated that “Emerging biotechs now face a tougher road to public markets.” [4]
➡️Why has there been significantly less Biotech IPOs in the US and why are these fewer and fewer IPOs coming at later stages of drug development?
For answers, lets look at an article titled “Shorting Innovation” by Nancy Kim and published by the Loyola of Los Angeles Law Review. [5] Ms. Kim implies that public biotech companies are especially vulnerable to market manipulation and she goes into detail about one specific company, $NWBO. She states, in relevant part:
“Small biotechs are also uniquely vulnerable and appealing targets for short sellers….Their very high risk-reward nature, low volume, and lack of liquidity make small biotechs an appealing target for shorting and market manipulation.” [5]
Ms. Kim goes on to highlight the costs of predatory market tactics on society:
“These small biotechs contribute disproportionately to innovative research and development but face many obstacles on the road to regulatory approval. Short attacks exacerbate the challenges faced by small biotechs and impose significant costs on society.”
“Given the long odds of bringing a new drug successfully to market, the high costs of doing so, and the great societal need that small biotechs fill, short selling the stock of small biotech companies without further regulation is not justified by a short seller’s desire for profits.”
The study concludes, in part:
“A biotech seeking to develop a novel therapeutic faces daunting odds. The research and development costs are high, the FDA regulations and testing requirements are rigorous, and the time horizon is long. Small biotech companies are vulnerable to FUD in a way that larger companies are not, and shorting creates an incentive for FUD. The stock of small biotechs is volatile, and a precipitous drop in price often sets off a cascade of problems.”
➡️The Vulture Capitalist
South Korea, China and India all have positive biotech IPO trends. They also either ban naked shorting or have more stringent rules and/or transparency when it comes to shorting as compared to US markets. If Ms. Kim is correct, our US markets, and the vulture capitalists that operate within said markets, are stifling innovation so they can make profit by harming vulnerable biotech companies.
It's time to change this trend. Market transparency and reform is the answer.
[1]ey.com/content/dam/ey-unifie…
[2]ib.barclays/our-insights/tre…
[3]rsmus.com/insights/industrie…
[4]biopharmadive.com/news/biote…
[5]digitalcommons.lmu.edu/cgi/v…
Image 1: biopharmadive.com/news/biote…
Image 2: ey.com/content/dam/ey-unifie…
The Dapper DO retweeted
$NWBO
Spoofing is not "aggressive trading" or a "trading tactic" -
Spoofing is fraud
-7th Circuit
What do the market makers Northwest Biotherapeutics is suing for alleged spoofing do now that their case is in discovery and headed towards trial?
And do those posts get entered into discovery?
It just got a whole lot more interesting
“....This staggering decline of 78 per cent in the price on a day with extremely positive news about the company was caused by defendants’ relentless and brazen manipulation of the market for NWBO shares,” lawyers at Cohen Milstein Sellers &Toll added.
. . .
“It’s already underhanded to engage in market manipulation, but to do so at the expense of cancer patients, some of whom have no other treatments to place their hopes on, is unconscionable,” said Laura Posner, a partner at Cohen Milstein...."
@CohenMilstein
$NWBO @kshaughnessy2
Potential future of $NWBO litigation: $NWBO (plaintiff) v. Citadel/Virtu/etc.
Here’s how the 7th Circuit’s August 2025 decision (affirming that spoofing = fraud under the federal wire fraud and commodities fraud statutes) could affect the NWBO spoofing case in S.D.N.Y.:
⸻
1. Bolsters “fraud” characterization
•The defense in NWBO has argued that spoofing is just “aggressive trading” or “lawful order placement.”
•Now, plaintiffs can point to the Seventh Circuit’s holding that spoofing is not only manipulative, but also A SCHEME TO DEFRAUD under federal law.
•That helps frame spoofing as inherently deceptive conduct, making it easier to survive dismissal or summary judgment.
⸻
2. Strengthens scienter (intent) arguments
•NWBO must show defendants intended to mislead the market with their orders.
•The 7th Circuit opinion explained why spoofing is inherently deceptive intent (placing orders you never plan to fill).
•Plaintiffs can now cite appellate precedent to argue that intent to defraud can be inferred from the spoofing pattern itself.
⸻
3. Influences how judges view plausibility
•The NWBO judge already let some spoofing claims proceed, but defendants will keep pressing the argument that “plaintiffs don’t plead fraud with particularity.”
•With the 7th Circuit ruling, plaintiffs can argue that courts nationwide are recognizing spoofing as real fraud, not just market noise, which makes their pleadings more credible.
⸻
4. Potential jury instruction impact
•If NWBO gets to trial, jurors will need instructions on what spoofing means.
•Plaintiffs may ask the S.D.N.Y. judge to borrow language from the 7th Circuit decision, showing that higher courts view spoofing as classic fraudulent manipulation.
•That reduces defense room to argue spoofing is legal or ambiguous.
⸻
5. Limitations
•The 7th Circuit decision was a criminal case (wire fraud, commodities fraud). NWBO’s suit is civil securities fraud.
•Different statutes, different standards of proof — but the fraudulent nature of spoofing cuts across both!
•Defendants may argue: “That was futures, not equities; that was criminal law, not securities law.” But the FRAUD logic still translates well.
⸻
✅ Bottom line: The 7th Circuit ruling doesn’t decide NWBO’s case, but it gives powerful appellate authority that spoofing is by definition a deceptive, fraudulent scheme. That makes NWBO’s claims stronger going forward and harder for defendants to dismiss as “normal trading.”
The Dapper DO retweeted
Three former JP Morgan traders lose their appeal to overturn their fraud convictions
"The White Collar Appeal: Seventh Circuit Holds Spoofing is Fraud"
"...three former JPMorgan commodities traders argued that their spoof orders did not misrepresent an “essential element of the bargain” and therefore did not qualify as a scheme to defraud.
The Seventh Circuit rejected that argument...
The government also elicited testimony from the defendants’ JPMorgan coworkers that the defendants had taught them how to spoof; that the defendants became angry when market participants executed their spoof orders before they could cancel them; and that, after a meeting where JPMorgan compliance officials warned traders to stop spoofing because regulators were investigating, one defendant exclaimed “[t]here goes the business”; and one defendant coached a witness prior to a compliance review by saying, “Remember, every order we placed, we intended to trade"...."
Convicted former JP Morgan trader reports to prison in January. His boss also sentenced to prison
“JPMorgan’s former gold trader Gregg Smith,
a convicted former JPMorgan Chase executive was sentenced to nearly two years in prison on Tuesday — the stiffest prison term given to an individual since the government’s crackdown on market manipulation.
His boss, Michael Nowak, was also convicted but was sentenced to one year and one month on Tuesday, according to Bloomberg.
Smith, 57, was described by an assistant US attorney as “the most prolific ‘spoofer’ that the government has prosecuted to date” for orchestrating an illegal scheme where he placed bogus market orders with no intention of carrying out the transactions, Bloomberg reported.
Spoofing causes market prices to go up or down, at which point the trader cancels the sale and places an opposite bet in an effort to manipulate share price — a blatant violation of the Securities and Exchange Commission’s rules.
Nowak, meanwhile, was described as “the boss” behind the scheme.”
The Dapper DO retweeted
$NWBO trading data (10/24/12–8/25/25):
•Reported OTC/Lit:
5.36B shares traded during that period
↳ Shorts: 2.41B (44.98%)
•Dark pools est.:
~3B shares (≈40–50% of all trading)
•Naked shorts (OTC + dark): ~2.7–3B shares
👉 That’s 2–3× NWBO’s float in synthetic supply and that explain why bashers on Ihub are active
24h/d on the stock.
If forced to cover, a short squeeze could be explosive.
#NWBO #DCVax #ShortSqueeze
The Dapper DO retweeted
$NWBO
"You can suppress a ticker. You can’t suppress a cure.”
...As one investor put it: “Holding NWBO feels like holding a beach ball underwater.
The longer it’s held, the faster it rockets when released.”...
NWBO has lived in paradox: strong science, quiet stock.
Structure has weak points, and they are nearing stress.
NWBO’s story is not just about one company.
It is about how modern markets can silence breakthroughs through invisible plumbing — and how eventually, reality asserts itself.
When the pipes flip, the world will not ask why NWBO was so loud.
It will ask how it stayed so quiet for so long."
🕵️📉 The Containment Thesis: Why $NWBO #DCVax Trades Quiet in Plain Sight
🌍 Part I — A Market That Can Silence Science
Northwest Biotherapeutics is not a typical biotech. It has a Phase III trial in glioblastoma published in JAMA Oncology showing survival plateaus that other drugs have never delivered. It has a GMP-licensed facility at Sawston, approved to make patient-specific therapies under UK law. It has automation through Flaskworks that solves the biggest challenge in autologous cell therapy: reproducibility and cost. By any scientific and operational measure, NWBO has built what many thought impossible.
And yet, in the stock market, NWBO trades at pennies on the over-the-counter (OTC) market, bypassed by analysts, ignored by index funds, and muted by mainstream media. The contradiction is glaring. How can a company with credible late-stage data and licensed manufacturing infrastructure remain priced like a lottery ticket?
The answer is not in the science. It lies in the structure of modern markets. To understand NWBO’s silence, you need to look at how today’s trading pipes work — and how they can be used to contain a stock.
🧱 The Architecture of Containment
Markets are not a flat playing field. They are a layered system of venues, rules, and incentives.
Venue. Companies on Nasdaq or NYSE are automatically included in index funds and parsing algorithms. By contrast, OTC companies sit outside these pipes, invisible to institutions and analysts.
Cadence. Markets reward a steady drip of machine-readable disclosures. Companies like NWBO that wait for peer-reviewed journals or regulatory clarity create fewer hooks for algorithms and media.
Settlement. The U.S. clearing system, run by DTCC, uses Continuous Net Settlement (CNS) to net billions of trades daily. This efficiency also hides delivery failures, letting synthetic shares persist. Regulators themselves acknowledge that fails can disappear in netting .
Together, these layers form the pipes of containment. Venue mutes visibility. Cadence starves algorithms. Settlement loopholes create fake supply. The result: a company can build world-class science while its stock remains structurally silenced.
🧠 Naked Shorts: The Phantom Supply Problem
In a normal short, a trader borrows shares before selling them, so the buyer receives a legitimate share. In a naked short, the trader sells without borrowing. The buyer sees shares in their account, but in reality those shares may not exist. Multiple people can believe they own the same stock .
NWBO’s own lawsuit alleges persistent naked shorting and spoofing, creating synthetic supply that suppressed its stock. This is the first pillar of containment: a float quietly inflated by IOUs.
📉 Why NWBO Fits the Pattern
At times, reported short interest in NWBO exceeded its entire public float — mathematically impossible without naked shorts. Analysts and retail DD threads cite this as a hallmark of suppression. Every milestone — peer-reviewed data, Sawston licensure, Specials approval — has been met with algorithmic short attacks, described as surges of tiny sell orders walking the price down.
Naked shorts create the ammunition. High-frequency algorithms deploy it. DTCC settlement nets it away. Together, they ensure extraordinary science barely moves the stock.
📑 Part II — Fails, Ex-Clearing, and the Hidden Short Problem
❌ What Are Fails-to-Deliver?
Normally, trades must settle in two days. If not, the failure is recorded as an FTD. In naked shorting, fails become structural. On paper, investors see positions in their account. In reality, no share arrived.
🔄 Ex-Clearing: Where Fails Go to Hide
Trades can bypass DTCC netting through “ex-clearing,” where brokers settle privately. Regulators have acknowledged they do not track these arrangements . Once a fail goes ex-clearing, it may never be reconciled.
NWBO has appeared on SEC threshold lists, but disappearing from the list does not mean fails vanished — more likely they migrated off-record.
📉 How Fails Suppress Price
Fails inflate supply. Millions of synthetic shares sold but never delivered expand the float and depress the price. Reddit DDs estimate real fails can be 10–15x reported figures .
For NWBO, this explains why even major catalysts have not lifted price. Buying pressure disappears into hidden fails, leaving science overshadowed by mechanics.
🌑 Part III — Dark Pools and the Art of Hiding Demand
🔒 What Are Dark Pools?
Dark pools are private trading venues designed to let institutions trade blocks without tipping off the market . They execute at the midpoint of the bid-ask spread, with the final trade reported after the fact .
In principle, they reduce volatility. But when used selectively, they mute demand and amplify supply.
⚖️ The Buy-Sell Routing Trick
Retail brokers often sell order flow to market makers. Buy orders can be routed to dark pools, never hitting the tape. Short sales, meanwhile, are routed to lit markets. The result: selling pressure is public, buying is hidden.
Redditors call it “hiding the buys, showing the sells.”
📊 NWBO and the Dark Pool Flood
Analyses show as much as 70% of NWBO’s daily volume takes place in dark pools. This mirrors U.S. equity markets more broadly, where dark pools and internalizers accounted for over 50% of stock trades by January 2025 .
For NWBO, investors report buying tens of thousands of shares without moving the price — because the trades are internalized in dark venues. Meanwhile, algorithmic sell bursts hit the lit tape, walking price down penny by penny.
🤖 Algorithms as Enforcers
Dark pools hide the buys. Algorithms enforce the walkdowns. Spoofing, layering, and wash trades — all named in NWBO’s lawsuit — systematically suppress upward moves.
Each time NWBO produced positive science, the stock spiked briefly before cascading back down under algorithmic pressure.
🏦 Part IV — The Black Hole of Settlement
The DTCC’s Continuous Net Settlement (CNS) nets buys and sells across brokers . This reduces cash movement but hides fails-to-deliver. A short sale that should create a fail can be masked by surplus shares at the broker.
Reddit DDs call this the “black hole of settlement.” Fails vanish into netting, never forcing a buy-in.
For NWBO, this explains why short pressure persists despite fleeting appearances on threshold lists. Once fails slip into CNS or ex-clearing, they are invisible.
🔮 Part V — The Breaking Point
Containment cannot last forever. Synthetic supply can mute demand, but reality eventually collides with structure.
For NWBO, forcing events could include:
1.Regulatory approval by MHRA or FDA.
2.NICE reimbursement, turning DCVax into commissioned therapy.
3.Uplisting to Nasdaq/NYSE, forcing index inclusion.
4.Legal discovery, exposing naked short records.
Redditors compare containment to a dam: water builds until it breaks. For NWBO, the science itself is the forcing function. “You can suppress a ticker. You can’t suppress a cure.”
🧭 Investor Perspective
Containment is both warning and opportunity. It explains why the stock has languished, but also why revaluation could be extreme when suppression breaks. As one investor put it: “Holding NWBO feels like holding a beach ball underwater. The longer it’s held, the faster it rockets when released.”
🔑 Synthesis
• Naked shorts create counterfeit supply.
• Ex-clearing hides fails.
• Dark pools mute demand.
• CNS netting balances the system.
• Forcing events break the loop.
NWBO has lived in paradox: strong science, quiet stock. Structure has weak points, and they are nearing stress.
🧾 Epilogue: Silence Before the Signal
NWBO’s story is not just about one company. It is about how modern markets can silence breakthroughs through invisible plumbing — and how eventually, reality asserts itself.
When the pipes flip, the world will not ask why NWBO was so loud. It will ask how it stayed so quiet for so long.
📚 Sources
• JAMA Oncology (Nov 2022), Liau et al. — DCVax-L Phase III glioblastoma results.
• Northwest Biotherapeutics SEC filings (2023–2025).
• UK Statutory Instrument 2025 No. 87 — MHRA ATMP framework.
• Brain Tumour Research (2024–2025).
• U.S. NCI / SEER data.
• Italian Cancer Registry Study (2017–2022).
• SIX Group (2025) — Dark Pools Explained .
• Wikipedia (July 2025) — Dark Pool (history, regulation, >50% U.S. trades in dark venues) .
• Reddit DD threads — r/Superstonk, r/NWBO, r/investing, r/CLOV.
• NWBO v. Market Makers (2022–present).
⚖️ Disclaimer
This briefing is for informational purposes only. It synthesizes public data, regulatory documents, academic sources, and community research. It is not investment advice or a guarantee of outcomes. Investors should do independent due diligence and consult licensed advisors. Patients should seek guidance from qualified medical professionals.
The Dapper DO retweeted
$NWBO
a David vs Goliath battle against greed in its ugliest form - allegedly trying to destroy a small public company with a promising brain cancer treatment.
The Goliaths couldn't stop the market manipulation lawsuit and the case is now in discovery
"The parallels to The Big Short are uncanny.
... in both cases, the moral hazard is stark: in 2008, bankers grew rich while millions lost homes; in NWBO’s case, traders allegedly profited while patients waited for innovation
Tens of millions of baiting orders left investors believing the company was a penny stock with no demand.
Just as mortgage brokers kept selling loans that everyone knew would default, spoofing created the appearance of endless supply when real buyers existed
Every story has a crack-the-glass moment.
In 2008, it was Lehman Brothers’ collapse. By then, no one could deny the system was rotten. The house of cards collapsed, defaults cascaded, and the AAA labels were revealed as fiction.
For NWBO, that day was May 10, 2022.
The company presented statistically significant Phase 3 results for DCVax-L in glioblastoma—a therapy that, for the first time in decades, showed survival benefit in both newly diagnosed and recurrent disease.
In a rational market, that should have been the equivalent of Burry’s CDS paying out.
Instead, the stock collapsed 78 percent in a single day, from $1.73 to $0.3862.
The optics of May 10 echo Lehman.
It was the day reality and price diverged most violently.
A breakthrough therapy was priced as failure, just as AAA securities were priced as safe days before they collapsed
Discovery is now the turning point.
For Burry, vindication came when default data surged through the system.
For NWBO, it will come when order logs, code, and chat transcripts are revealed. If they show traders stacking and canceling orders with intent, the illusion is broken. It becomes not just a story of weak stock but of deliberate manipulation...."
-@andrewcaravello
____________
July 2025
Why doesn't the @MiamiHerald even mention that Ken Griffin's company, Citadel Securities, is being sued for alleged market manipulation by Northwest Biotherapeutics, which has a promising treatment for brain cancer??
xitter.cf/kshaughnessy2/status/1…
🔥 The Biggest Short: How $NWBO #DCVax Exposes a Market Rigged Like 2008 @MichaelJBurry__
$GME vs #NWBO @TheRoaringKitty
From meme-stock mayhem to a cancer therapy’s fight for fair value
How a @wallstreetbets short squeeze became a movie—while a cancer breakthrough’s struggle against market manipulation became a federal court case.
🎬 Introduction — From Subprime to Spoofing
In 2015, Adam McKay’s The Big Short took audiences inside the surreal world of the U.S. housing bubble. Michael Lewis’s book and McKay’s film showed how a few contrarian investors, like Michael Burry, pieced together what the world refused to see: that mortgage-backed securities stamped AAA were in fact toxic. The movie made its point with cameos—Margot Robbie in a bubble bath explaining mortgage bonds, Selena Gomez at a blackjack table showing how side bets ripple through an economy, Anthony Bourdain comparing old fish in stew to subprime loans hidden in CDOs . It was about illusions that looked solid until they collapsed.
Two decades later, another story is playing out—different asset, same structure. Instead of mortgages, the subject is cancer innovation. Instead of CDOs, the instrument is alleged spoofing. And instead of banks hiding risk in tranches, it is market makers allegedly hiding true demand behind layers of fake sell orders. Northwest Biotherapeutics ($NWBO), a clinical-stage biotech developing a dendritic cell vaccine for glioblastoma, has accused Citadel, Virtu, and others of a multi-year scheme that suppressed its share price while it struggled to fund trials. In March 2025, a federal judge ruled that NWBO’s most direct claims could proceed, opening the door to discovery of order-level data and algorithms.
The parallels to The Big Short are uncanny. In both cases, insiders exploited opaque systems. In both cases, the fundamentals were ignored—mortgage defaults in one, published survival benefit in brain cancer in the other. And in both cases, the moral hazard is stark: in 2008, bankers grew rich while millions lost homes; in NWBO’s case, traders allegedly profited while patients waited for innovation.
This is not just a short. It is the biggest short: a years-long divergence between reality and price, where the reckoning, once forced, will not be incremental but structural.
🧬 DCVax-L — Fundamentals Hidden Behind the Façade
Michael Burry’s insight in 2005 was simple but radical: look at the fundamentals. Adjustable-rate mortgages were resetting, defaults were rising, and yet securities backed by those loans were still rated AAA . The labels didn’t match reality.
NWBO’s fundamentals show a similar disconnect. Glioblastoma multiforme (GBM) is among the deadliest cancers, with median survival of just 15–18 months and a five-year survival rate under 7 percent. No therapy has shifted this plateau in decades. And yet NWBO’s lead product, DCVax-L, has done precisely that. In a 331-patient Phase 3 trial spanning the US, UK, Germany, and Canada, DCVax-L extended median survival to 19.3 months in newly diagnosed GBM and 13.2 months in recurrent disease. A “long tail” of survivors at five years—13 percent of the newly diagnosed cohort—marked a break from decades of futility. The results were published in JAMA Oncology in November 2022, peer-reviewed and statistically significant. Safety was excellent, with no treatment-related deaths.
These are fundamentals. A therapy that works, validated in one of oncology’s hardest tumors. Yet the stock price moved as if nothing had happened. Trial success in May 2022, the JAMA Oncology paper, even the 2023 GMP license for NWBO’s Sawston, UK facility—events that should have catalyzed value—coincided with collapses. On May 10, 2022, when results were publicly presented, the stock fell 78 percent in one day.
The analogy is direct. Just as CDOs received AAA stamps while full of rot, NWBO’s results were met with a price collapse as if worthless. In both cases, the labels and the reality diverged.
⚙️ Manufacturing and the Regulatory Rails
The Big Short showed that the system’s complexity—tranches, swaps, synthetics—wasn’t just noise, it was the mechanism of distortion. For NWBO, the mechanism isn’t financial engineering but regulatory architecture.
DCVax-L is process-defined, not a pill. It requires patient-specific manufacturing under GMP standards. NWBO built Sawston, a state-of-the-art facility run by Advent BioServices, and in March 2023 received an MHRA license for commercial manufacture of cell therapies. More importantly, the UK has created the regulatory rails for scale. In 2014, DCVax-L became the first therapy to win the UK’s Promising Innovative Medicine (PIM) designation. In 2025, the UK enacted SI 87, explicitly legalizing point-of-care autologous therapies: medicines made “at or near” the site of use for serious conditions. Under SI 87, NWBO can deploy DCVax-L through “Specials” and real-world evidence programs before full market authorization.
This matters because it means NWBO is not waiting on theory. The rails exist. The facility is licensed. The law is written. The fundamentals are in place for a therapy to reach patients. And yet the stock trades as if nothing of value exists.
🎭 The Hidden Mechanism — Spoofing as the New CDO
In the film, Ryan Gosling’s character explains tranches with a Jenga tower: pull out the bottom blocks, and the top crashes. Spoofing works the same way. By stacking fake orders in the book, market makers can make the whole structure look solid—until the moment they cancel, and the blocks vanish.
NWBO alleges that between 2017 and 2022, this happened on 395 trading days. The cycle was mechanical: flood the market with fake sells, trigger real selling, buy at the dip, cancel the fakes. Over years, it created a synthetic history of weakness. Tens of millions of baiting orders left investors believing the company was a penny stock with no demand. Just as mortgage brokers kept selling loans that everyone knew would default, spoofing created the appearance of endless supply when real buyers existed.
It is, in effect, the same game: complexity and illusion used to distort reality. In one, it was synthetic CDOs. In the other, synthetic liquidity. In both, the fundamentals were buried beneath noise designed for profit.
⚖️ The Lawsuit — Betting Against the Illusion
In The Big Short, Michael Burry’s bet was lonely. He invented credit default swaps to short mortgage bonds, paying premiums while housing prices kept climbing. His investors revolted. They called him crazy, demanded their money back, even threatened lawsuits. But Burry had seen the numbers: defaults were already ticking higher .
NWBO’s lawsuit is the same kind of contrarian bet—except instead of swaps, it is litigation. On December 1, 2022, Northwest Biotherapeutics sued Citadel Securities, Virtu Americas, GTS, G1 Execution Services, Canaccord Genuity, Instinet, and Lime, alleging systematic spoofing between 2017 and 2022. According to the complaint, on 395 of 1,171 trading days, defendants placed tens of millions of fake orders, creating the illusion of overwhelming supply.
The pattern was mechanical: large baiting sells placed just above the market, triggering real traders to sell, then genuine buys scooping up shares at the dip, followed by cancellation of the fakes. This wasn’t liquidity—it was theatre. Just as synthetic CDOs made junk look solid, spoofing made demand look absent.
NWBO’s position is the same as Burry’s: the fundamentals are clear, but the market refuses to price them. In 2005 it was mortgage defaults. In 2022 it was peer-reviewed cancer survival data. Both were ignored in favor of the illusion.
📉 May 10, 2022 — The Lehman Moment
Every story has a crack-the-glass moment. In 2008, it was Lehman Brothers’ collapse. By then, no one could deny the system was rotten. The house of cards collapsed, defaults cascaded, and the AAA labels were revealed as fiction.
For NWBO, that day was May 10, 2022. The company presented statistically significant Phase 3 results for DCVax-L in glioblastoma—a therapy that, for the first time in decades, showed survival benefit in both newly diagnosed and recurrent disease. In a rational market, that should have been the equivalent of Burry’s CDS paying out. Instead, the stock collapsed 78 percent in a single day, from $1.73 to $0.3862.
The complaint describes “relentless and brazen manipulation.” Data showed layer upon layer of fake sells overwhelming real buyers. To an outsider, it looked as if the science had failed. But later that year, JAMA Oncology published the peer-reviewed results: survival was real, benefit was real, the therapy worked.
The optics of May 10 echo Lehman. It was the day reality and price diverged most violently. A breakthrough therapy was priced as failure, just as AAA securities were priced as safe days before they collapsed.
⚖️ Narrowing the Case, Strengthening the Bet
Burry’s genius was persistence. He refused to close his swaps even as losses mounted, because he knew the math would turn. In the film, he locks investors into the fund, stopping withdrawals until the market cracked. His narrow, concentrated bet was brutal to endure, but explosive when it paid .
Judge Gregory Woods’s March 26, 2025 ruling did something similar for NWBO. He dismissed the broadest claim of “persistent depression” but preserved the core: that NWBO sold tens of millions of shares at closing prices manipulated by spoofing. This narrow focus is powerful. It ties damages to specific days and specific acts, the most provable ground.
Discovery is now the turning point. For Burry, vindication came when default data surged through the system. For NWBO, it will come when order logs, code, and chat transcripts are revealed. If they show traders stacking and canceling orders with intent, the illusion is broken. It becomes not just a story of weak stock but of deliberate manipulation.
That is NWBO’s credit default swap moment—the quiet contract that flips once reality can no longer be denied.
🕹️ Suppression, Squeezes, and Systemic Distortion
GameStop’s short squeeze was the mirror opposite dynamic. In January 2021, a feedback loop of short interest and retail call buying sent the stock vertical, only to revert. It was positioning-driven, not fundamentals-driven.
The housing bubble was false inflation—CDOs rated AAA when they were toxic. GameStop was forced covering—a reflexive loop of supply and demand. NWBO is hidden suppression: a biotech with positive data allegedly held down for years by spoofing.
GameStop reshuffled wealth. The housing collapse destroyed homes and jobs. NWBO’s stakes are deeper: alleged manipulation that may have delayed the advance of a therapy extending lives in glioblastoma.
That contrast matters. GameStop revealed what happens when short interest is visible. The Big Short revealed what happens when toxic assets are hidden inside complexity. NWBO reveals what happens when spoofing hides demand in plain sight, distorting capital formation in an OTC market where surveillance is weak.
⚖️ Discovery — The Balance Sheets of Market Makers
Judge Woods’s ruling means NWBO will now see the equivalent of the banks’ hidden balance sheets. Discovery will bring order-level trade logs, algorithmic code, and internal communications.
For Citadel, Virtu, and others, that is perilous. Just as Morgan Stanley’s books revealed exposure to collapsing derivatives in 2008, these records could reveal exposure to manipulative practices. If intent is documented, it forces regulators to explain why spoofing in equities went unchecked even as it was prosecuted in futures and metals.
The implications stretch beyond one biotech. If NWBO proves its case, other issuers may follow. Regulators may be forced to extend surveillance tools to OTC markets. And market makers may have to hard-code compliance barriers to prevent order patterns resembling spoofing.
💰 Capital, Moral Hazard, and Why This Is The Biggest Short
In 2008, the moral hazard was banks profiting from junk while families lost homes. In 2025, the hazard is traders profiting from manipulation while patients lose time.
For NWBO, every suppressed raise meant more dilution and slower expansion. A fair valuation would have enabled faster scaling at Sawston, more trials, and earlier delivery of DCVax-L under the UK’s Specials framework. The opportunity cost is measured not in basis points but in patient survival curves.
If the dam breaks, the correction will not be a meme spike. It will be a structural repricing, anchored by fundamentals: published data, a licensed GMP facility, and a regulatory pathway for global deployment. Unlike GameStop, the repricing here would be durable, because it is tied to cash flows and patient demand.
That is why this is the biggest short. Because it is not only about securities—it is about whether the market’s plumbing actively obstructed medical progress. Just as Michael Burry endured ridicule until vindicated, NWBO has been dismissed as a penny stock until now. Both saw truths the market refused to price. Both endured pain waiting for recognition. And when it comes, the correction is sudden and structural, not incremental.
📚 Sources
•The Big Short (film), dir. Adam McKay, 2015 .
•Investopedia, “The Big Short Explained” .
•Federal filings in NWBO v. Canaccord et al., SDNY.
•JAMA Oncology (Nov 2022), Liau et al., DCVax-L Phase 3 results.
•UK MHRA PIM designation (2014), Advent Bio GMP license (2023), SI 2025/87 modular manufacture law.
⚠️ Disclaimer
This narrative is based on public court filings, peer-reviewed publications, regulatory documents, and reputable press. It is intended for educational purposes only and does not constitute legal, investment, or medical advice. Allegations described remain unproven unless and until established by a court or admitted by the parties.
The Dapper DO retweeted
🚀 #DCVax-L Takes the Plenary Stage — Why Dr. Linda Liau’s Title Signals the Turning Point for $NWBO.
📜 Regulatory silence is not rejection
If October 14 arrives without a public MHRA decision, the core thesis does not change. The scientific review has already been completed, as reflected by the MHRA’s FOI reply confirming that a brain cancer medicine was discussed at CHM in May or June and that the minutes are being withheld under Section 22(1) for future publication. NICE’s July letter added that Northwest Biotherapeutics is still fully occupied and engaged with the MHRA and not yet in a position to submit evidence. These are closing-stage process signals.
The thesis would only change with a formal rejection or credible public evidence that the application is no longer viable. Neither has occurred.
Additional context on MHRA publication cycles:
The MHRA does not update its approvals database in real time. Instead, it issues lists in two batches each month:
• approvals granted from the 1st to the 14th
• approvals granted from the 15th to the end of the month
And these lists are published with a delay. For example:
• approvals granted May 15–31 were published on June 10
• approvals granted June 1–14 were published on July 9
This means that even if an approval is granted internally, it may not appear publicly for 3–4 weeks. What investors see on the MHRA website is the lagging disclosure, not the live decision date.
Looking ahead, the cycles fall like this:
•August 15–31 approvals → expected publication late September
•September 1–14 approvals → expected publication mid-to-late October
•September 15–30 approvals → expected publication late October to early November
This is why apparent silence should not be misread as inaction, the process is structured around delayed publication.
When do companies PR?
Companies almost never wait for the MHRA’s public lists. They issue a press release (RNS) as soon as they receive the formal authorisation letter. The monthly MHRA PDF is just the archival record that comes later.
• Example: Jazz Pharmaceuticals PR’d its MHRA approval for Epidyolex on the same day the letter was received, weeks before it appeared on the MHRA site.
• Example: Novartis did the same with Kymriah — company PR first, MHRA database later.
👉 The real sequence is: MHRA notifies the company → company PR → MHRA list update.
For NWBO, this means the decisive signal will be their own announcement. The half-month “lists” are confirmation after the fact.
⏳ False deadlines versus regulatory time
Investor calendars often collide with the slower rhythm of regulatory drafting. Labels can bounce between sponsor and agency over wording, pharmacovigilance structure, or risk management detail. That is procedural, not scientific. If October passes quietly, it points to final drafting, not failure.
🧑⚕️ Why the title and the stage matter
The strongest tell is not just the words in the title — it’s where those words will be spoken. Dr. Linda Liau’s CNS plenary is titled Bench to Bedside: Evolution of Clinical Trials — DCVax-L for Primary and Recurrent GBM. This is the first time DCVax-L has ever appeared in the title of one of her presentations.
And it is not on a minor stage. It is scheduled for the plenary session of the 75th Annual Congress of Neurological Surgeons (CNS), the centerpiece event of the largest neurosurgical meeting in the world. More than 11,000 neurosurgeons and neuro-oncologists from over 90 countries attend. The plenary is where practice-changing therapies are introduced, guidelines are seeded, and new standards of care are declared. For brain cancer, there is no more prestigious or influential platform.
In oncology broadly, ASCO’s plenary is the summit stage. In neurosurgery, CNS plenary is its equal — the “supreme court” for brain tumor care. For a therapy like DCVax-L, CNS plenary is not second best, it is the most relevant and authoritative forum it could debut in.
And here is what makes it even more weighty: CNS plenary titles are historically more conservative than ASCO’s. Neurosurgery is a smaller, tighter field, and its societies have been more reluctant to allow brand names in titles before approval. ASCO, with its broader oncology footprint, has seen big immunotherapy names like Keytruda enter plenary programs within a cycle of approval. But CNS is rarer ground: the fact that DCVax-L is now in the title of its plenary is unusual, harder to achieve, and therefore even more significant.
🧪 The Bosch contrast
Just four months earlier, in June 2025, Northwest’s own scientific leadership stayed generic in public titling. Marnix L. Bosch and Lekhana Bhandary presented Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses, under the Northwest Biotherapeutics banner. Notice what is absent: the title does not say DCVax-L.
That was the standard approach pre-approval — generic language, no branding, consistent with society rules and scientific convention. The leap from Bosch’s generic June title to Liau’s branded October CNS plenary title shows how far the product has moved in just a few months.
📜 The rules — codified, not speculation
This is not just investor interpretation — it is codified policy.
•ASCO: “Do not use proprietary or trade names in the title or abstract. Use only generic names of drugs and devices.”
•ESMO: “Commercial names of drugs are not allowed in the title. Only the generic name (INN) is permitted.” A brand may appear in parentheses inside the abstract text, never in the title.
•CNS: The 2025 CNS abstract submission guidelines, aligned with ACCME standards, require educational materials to use generic names, not product or drug trade names. If a brand must be cited, the presenter must either (a) list multiple trade names for balance, or (b) prove that the product is the only or best of its class.
In practice, CNS has followed the same convention as ASCO and ESMO: past programs show no single proprietary product names in titles pre-approval.
Examples:
•2022: Phase III DCVax-L trial results were presented under the title Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma, not “DCVax-L.”
•2024: Diakonos Bioscience presented its vaccine DOC1021 under the descriptive title Vaccination by homologous antigenic loading as adjuvant therapy for glioblastoma: Early analysis of phase 1 results, again avoiding the proprietary name.
•Even for technologies like tumor treating fields, CNS abstracts historically used the class name “TTFields” rather than the device’s brand “Optune,” or else paired multiple names (e.g. Gamma Knife vs. CyberKnife) to satisfy balance requirements.
The pattern is consistent: brand names do not appear in CNS titles before approval. That is why Liau’s 2025 plenary, naming DCVax-L outright, stands out.
🔍 External proof: timing from other blockbusters
The same naming arc has played out in every major immunotherapy — and the timing is tight.
Keytruda (pembrolizumab, Merck MK-3475)
•Pre-approval: NEJM 2013 used “lambrolizumab (MK-3475).” ASCO 2013–2014 abstracts the same.
•Approval: FDA accelerated approval Sept 4, 2014 (melanoma).
•Brand-name usage: Sept 2014 press release, “FDA Approves KEYTRUDA (pembrolizumab).” By ASCO 2015, plenary titles and press briefings featured Keytruda by name.
👉 Brand name moved into plenary within 6–9 months of approval.
Kymriah (tisagenlecleucel, Novartis CTL019)
•Pre-approval: ASH 2014–2016, “CTL019.” NEJM 2014: “CTL019 in B-ALL.”
•Approval: Aug 30, 2017 (pediatric ALL).
•Brand-name usage: Sept 2017, Novartis press: “Kymriah approved.” ASH 2017 presentations: “tisagenlecleucel (CTL019, Kymriah).”
👉 Brand name first appeared on plenary stage the same quarter as approval.
Zolgensma (onasemnogene abeparvovec, AVXS-101)
•Pre-approval: 2016–2018 abstracts used “AVXS-101.” NEJM 2017: “AVXS-101 gene replacement.”
•Approval: May 24, 2019 (SMA).
•Brand-name usage: FDA press release, “FDA approves Zolgensma,” same day. Cure SMA 2019 conference: “onasemnogene abeparvovec (Zolgensma).”
👉 Brand appeared instantly at approval; first major conference after May 2019 used Zolgensma.
Abecma (idecabtagene vicleucel, bb2121)
•Pre-approval: ASH 2017–2020, always “bb2121.” NEJM 2021: “idecabtagene vicleucel (bb2121).”
•Approval: March 26, 2021 (multiple myeloma).
•Brand-name usage: April 2021 press releases: “Abecma (idecabtagene vicleucel).” ASCO 2021 abstracts: “ide-cel (Abecma).”
👉 Brand name entered conference titles in the same cycle as approval.
Average timing across all four examples: 0–9 months from approval to first brand-name plenary mention. In practice, almost always the very next major conference cycle.
🌍 October as an inflection, not a cliff
October 14 is not a regulatory deadline. It is an inflection point. If approval is public before or during Dr. Liau’s talk, CNS becomes the launchpad with 11,000 neurosurgeons as the first audience. If approval comes after, the fact that DCVax-L is being presented by name on the CNS plenary stage — while CHM minutes are still sealed under Section 22(1) — is itself the clearest signal of regulatory comfort.
The pillars remain:
•Scientific review is complete.
•Advent is licensed and ready to manufacture and export.
•MHRA is now a WHO-Listed Authority, unlocking reliance markets.
•The remaining step is SmPC finalisation and publication of the decision.
🎯 Bottom line
The risk is not that October passes quietly. The real risk would be rejection — and nothing in the record points that way.
What is new is that DCVax-L will be spoken by name, for the first time, on the plenary stage of the CNS Congress — neurosurgery’s supreme court, the highest platform where standards of care are introduced. Bosch could not use the name in June. Liau will in October.
And history is clear: Keytruda, Kymriah, Zolgensma, Abecma — all four made the same shift, from generic titles to branded plenary talks, right at the moment of approval. The average lag was zero to one conference cycle.
And because CNS plenary titles are historically more conservative than ASCO, the fact that DCVax-L is appearing here, by name, makes the signal even stronger. It is rarer, harder to achieve, and carries disproportionate weight.
That is why October matters. Not as a cliff, but as the moment the name itself walks onto the main stage — and history says that only happens when approval has already been secured internally.
Great pick-up by @metacollectiveG — this is the very first time in history that DCVax-L has appeared by name in the title of a scientific presentation. You heard that right — a scientific presentation.
📚 Sources & References
•CNS 2025 Abstract Submission Guidelines — educational materials must use generic names; trade names only if balanced or unique (ACCME aligned)
•ASCO Abstract Submission Rules — “Do not use proprietary or trade names in the title or abstract”
•ESMO Abstract Rules — generics required in titles; brand names only in parentheses inside text
•CNS 2022 Meeting — Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma (no DCVax-L)
•CNS 2024 Meeting — Vaccination by homologous antigenic loading… (no proprietary code used)
•Bosch, M. & Bhandary, L. (June 2025) — Next Generation Dendritic Cell Treatments… (no DCVax-L)
•Liau, L. et al. (2018) JAMA Oncology — “Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination…” (no DCVax-L)
•Merck (Sept 2014) — FDA Approves KEYTRUDA (pembrolizumab)
•Merck (May 2015) — New data for KEYTRUDA across 10 cancers (ASCO press)
•Novartis (2017) — CTL019 → Kymriah approval
•Novartis (2019) — AVXS-101 → Zolgensma
•BMS (2021) — bb2121 → Abecma
⚖️ Disclaimer
This analysis reflects interpretation of publicly available documents, historical precedent, and scientific society policies. It is not official confirmation from Northwest Biotherapeutics or any regulatory body. It should not be considered financial advice. Investors should conduct their own due diligence and rely on official regulatory announcements for definitive updates.
